Jazz hits dud note as midphase essential tremor test misses endpoint

[cafead]

via Jazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor trial to meet its primary endpoint. But the drugmaker saw numeric improvements and is waiting on the data from another study rather than immediately bringing the curtain down on the program.

article source